Tools   Select Another Resource Report Type

https://ncma.bigelow.org/

National marine phytoplankton collection, maintaining over 2700 strains from around the world, most are marine phytoplankton but they also have benthic, macrophytic, freshwater and heterotrophic organisms - now incorporating bacteria and viruses. Strain records have (when available): * collection and isolation information * culturing medium recipes and growth conditions * photographs * GenBank accession link * collection site map * link to the taxonomic database Micro*scope The deposition of new strains are welcome if the strains are a valuable addition to the collection. Examples include strains that are referred to in publications, contain interesting molecular, biochemical or physiological properties, are the basis for taxonomic descriptions, are important for aquaculture, or are from an unusual geographical location or ecological habitat. The NCMA offers a course in phytoplankton culturing techniques and facilities for visiting scientists are available at the new laboratories in East Boothbay, Maine. Services include: Mass Culturing DNA and RNA, Purification, Private Holdings, Culture Techniques Course, Visiting Scientists, Single Cell Genomics, Flow Cytometry, Corporate Alliances and Technology Transfer.

Proper citation: National Center for Marine Algae and Microbiota (RRID:SCR_002120) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/21

Data and biological samples were collected by this consortium organizing international efforts to identify genes that determine an individual risk of type 1 diabetes. It originally focused on recruiting families with at least two siblings (brothers and/or sisters) who have type 1 diabetes (affected sibling pair or ASP families). The T1DGC completed enrollment for these families in August 2009. They completed enrollment of trios (father, mother, and a child with type 1 diabetes), as well as cases (people with type 1 diabetes) and controls (people with no history of type 1 diabetes) from populations with a low prevalence of this disease in January 2010. T1DGC Data and Samples: Phenotypic and genotypic data as well as biological samples (DNA, serum and plasma) for T1DGC participants have been deposited in the NIDDKCentral Repositories for future research.

Proper citation: Type 1 Diabetes Genetics Consortium (RRID:SCR_001557) Copy   

•   Source: SciCrunch Registry

http://type1diabetes.jax.org/

International repository for importation, curation, genotypic and phenotypic validation, cryopreservation, and distribution of mouse stocks of value to the type 1 diabetes scientific community holding over 250 genetically modified or congenic mouse stocks that are being used to dissect genetic and biologic features of T1D. They provide extensive genotypic and phenotypic quality control and genetic stabilization for these strains, as well as incidence studies when available. An added value of T1DR stocks is their ability to propel advances in related areas of science, including research in non-T1D autoimmunity and infectious diseases. The staff provides information and technical assistance regarding selection and use of existing T1DR models, and will provide limited support for development of new models considered to be of high-value for the T1D community. The resource includes strains generated at the Jackson Laboratory as well as strains donated by external scientists. Investigators are highly encouraged to donate a strain to ensure its preservation and availability to other researchers.

Proper citation: Type 1 Diabetes Resource (RRID:SCR_001475) Copy   

•   Source: SciCrunch Registry

http://www.tigm.org/

Resource for any researcher looking to obtain knockout mice and embryonic stem (ES) cells quickly and with favorable intellectual property (IP) terms. Our resources include the world’s largest gene trap library of ES cells in the C57BL/6N mouse strain and a constantly expanding repository of cryopreserved germplasm of knockout lines. TIGM provides both ES cell clones and mice as well as other transgenic core services including CRISPR/Cas9-based genome modifications within the Texas A&M system and to the public and private international research community.

Proper citation: Texas A and M Institute for Genomic Medicine (RRID:SCR_001615) Copy   

•   Source: SciCrunch Registry

http://www.bari2d.org/

A multicenter randomized clinical trial that aims to determine the best therapies for people with type 2 diabetes and moderately severe cardiovascular disease. 2368 participants were randomized at 49 sites in 6 countries. All subjects were given intensive medical therapy to control cholesterol and blood pressure and given counseling, if needed, to quit smoking and to lose weight. Beyond that, they compared whether prompt revascularization, either bypass surgery or angioplasty, e.g. stents, was more effective than medical therapy alone. At the same time, they also looked at which of two diabetes treatment strategies resulted in better outcomes����??insulin-providing versus insulin-sensitizing - that is, increasing the amount of insulin or making the insulin work better. Only patients with known type 2 diabetes and heart disease that could be treated appropriately with a revascularization OR medical therapy alone were eligible for the trial. Patients entered the study between January 2001 ����?? March 2005 and were followed for an average of five years. When a patient entered the study, physicians first decided whether that patient should receive stenting or bypass surgery. The patient then received their randomization assignment. All patients were treated in BARI 2D for both their diabetes and heart disease, as well as other risk factors that might effect those diseases, regardless of which group they were in. Diabetes-specific complications including retinopathy, nephropathy, neuropathy, and peripheral vascular disease were monitored regularly. Tests, blood samples, urine samples, and treatment cost data were obtained periodically through the trial and examined by experts at 7 central laboratories and other research partners. Experts on risk factors routinely oversaw treatments of all patients at 4 central management centers. A panel of independent experts reviewed data every six months to make sure that all patients were receiving safe care.

Proper citation: BARI 2D (RRID:SCR_001496) Copy   

•   Source: SciCrunch Registry

http://teddy.epi.usf.edu/

International consortium of six centers assembled to participate in the development and implementation of studies to identify infectious agents, dietary factors, or other environmental agents, including psychosocial factors, that trigger type 1 diabetes in genetically susceptible people. The coordinating centers recruit and enroll subjects, obtaining informed consent from parents prior to or shortly after birth, genetic and other types of samples from neonates and parents, and prospectively following selected neonates throughout childhood or until development of islet autoimmunity or T1DM. The study tracks child diet, illnesses, allergies and other life experiences. A blood sample is taken from children every 3 months for 4 years. After 4 years, children will be seen every 6 months until the age of 15 years. Children are tested for 3 different autoantibodies. The study will compare the life experiences and blood and stool tests of the children who get autoantibodies and diabetes with some of those children who do not get autoantibodies or diabetes. In this way the study hopes to find the triggers of T1DM in children with higher risk genes.

Proper citation: TEDDY (RRID:SCR_000383) Copy   

•   Source: SciCrunch Registry

http://scicrunch.org/Aging

Portal devoted to aging relevant scientific data and resources.

Proper citation: Aging Portal (RRID:SCR_000496) Copy   

•   Source: SciCrunch Registry

http://narayanahospitals.com/cellsofhope/

Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (NHTB-SCRC) is a joint venture between Rotary Bangalore Health City (RBHC) and Narayana Hrudayalaya. Our mission is to create awareness on Cord Blood Banking among the masses. Our vision is to make sure that every pregnant mother in India is able to afford to bank her child''s cord blood and cord tissue in a novel form of ������??Biological Insurance������??. The center would also assist in research and development of newer stem cell therapies. These goals are met while ensuring patient safety and well being by maintaining compliance with ICMR guidelines, Good Manufacturing Practice (GMP) guidelines, strict confidentiality and adherence to ethical standards. The private cord blood bank would store cord-blood and cord tissue derived stem cells for the exclusive use of clients who would pay for the cryo-storage, for a period of 21 years. These samples would be used for the child or its siblings anytime in the future, for therapy of various medical conditions. The public cord blood bank would enable us to collect cord blood from delivery and birthing centers, process these specimens, type their HLA signature and store them in ultra-low temperature conditions for use on prospective recipients. These recipients would have to be matched against their HLA signature with the stored stem cell concentrate. Patients with a disease treatable by stem cell therapy would have to have their HLA type known and they approach us for treatment. Such patients would be matched against our library of samples to identify a suitable match which would then be issued at a nominal cost. The cost of therapy would however be separate and informed to the patient before embarking on the treatment.

Proper citation: Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center (RRID:SCR_010680) Copy   

•   Source: SciCrunch Registry

http://www.biobancusa.com/

BioBancUSA is a leading biotechnology company specializing in white blood cell collection, processing, cryopreservation and storage service. BioBancUSA, a private company headquartered in Monterey, California, is the exclusive licensee of the original patent for the collection, processing and cryopreservation technology of white blood cells, giving you the assurance of both technical integrity and legal legitimacy that you can count on. BioBancUSA is dedicated to providing our clients with the highest quality immune cell preservation for their future medical use. We are committed to the most advanced technology, exceptional, personalized service and leading-edge innovation to benefit our customers, health care providers, shareholders and employees.

Proper citation: Biobanc USA (RRID:SCR_010622) Copy   

•   Source: SciCrunch Registry

http://www.rucdr.org/

RUCDR is a biobank and a service organization that maintains human blood, serum, saliva, tissue and the genetic products derived from those. Services include technical consultation and logistical support for biobanking. Researchers can order biomaterials and apply for phenotypic / genotypic data.

Proper citation: Rutgers Cell and DNA Repository (RRID:SCR_010624) Copy   

•   Source: SciCrunch Registry

http://www.ntnu.edu/hunt

International biobank storing whole blood and DNA from 200,000 individuals, serum and plasma samples from more than 100,000 individuals as well as urine, RNA tubes, cells, buffy coat and Na-heparin tubes for environmental analysis for as many as 50,000 individuals. All bio-specimens from the HUNT surveys are collected, processed and stored at the HUNT Biobank in Levanger. The National CONOR Biobank is located on the same site, where it serves as a central research repository for DNA samples from all the largest Norwegian health surveys. These make up the Cohorts of Norway (CONOR), which include samples from more than 200,000 individuals. * HUNT 1 was carried out in 1984-1986 to establish the health history of 75,000 people. * HUNT 2, carried out in 1995-1997, focused on the evolution of the health history of 74,000 people. This included blood sample collection from 65,000 people. The data that accompany biospecimens in the biobank are stored in secured computer systems that run complex database management and analysis software. * HUNT 3 was completed in June 2008. 93,210 people were invited to participate in the study, and as of the 6th of June, 2008, 48,289 people participated (52% participation rate). The data, collected by means of questionnaires, interviews, clinical examinations and collection of blood and urine samples, will be ready for analysis in January 2009. * Young-HUNT is the adolescent part of HUNT including participants aged 13-19 years. Young-HUNT1 (1995-97) was conducted as part of HUNT2, 9141 adolescents participated (90% response rate). Young-HUNT2 (2000-01) was a follow-up study of Young-HUNT1, 2400 students participated in both studies (77% of the invited). Young-HUNT3 (2006-08) was a new cross-sectional study as part of HUNT3. This time 8677 adolescents participated (87% response rate). Data collection included self-reported questionnaires, structured interviews, clinical measurements and, in Young-HUNT3, buccal smears. All institutions with research expertise can apply for access to analyze HUNT data. Projects must have recommendations from The Regional Committee for Medical Research in Norway (REK) and be registered with The Norwegian Social Science Data Services (NSD).

Proper citation: Hunt Biobank (RRID:SCR_010626) Copy   

•   Source: SciCrunch Registry

http://mayoresearch.mayo.edu/mitochondrial-disease-biobank/

A biobank of blood and tissue samples from patients with known and suspected mitochondrial diseases along with data from their families. Samples are used in research to understand the family of mitochondrial disorders such as Alpers' syndrome, encephalopathy, and Friedrieich's ataxia, among many others. The goal of the biobank is to advance the understanding of mitochondrial disease and improve patient care.

Proper citation: Mayo Mitochondrial Disease Biobank (RRID:SCR_010598) Copy   

•   Source: SciCrunch Registry

http://www.lifelegacy.org

A non-profit tissue bank that facilitates the distribution of non-transplantable tissue to the medical and research community. It provides snap frozen low post mortem interval (PMI) tissue, normal and diseased tissue, plastinated specimens, anatomical specimens, and specialty specimens. The foundation also works to increase public awareness of research tissue donation for medical research.

Proper citation: LifeLegacy Foundation (RRID:SCR_000518) Copy   

•   Source: SciCrunch Registry

http://www.mhasweb.org/

A dataset of a prospective panel study of health and aging in Mexico. The study was designed to ensure comparability with the U.S. Health and Retirement Study in many domains, and the NHANES III. The baseline survey in 2001 is nationally representative of the 13 million Mexicans born prior to 1951. The six Mexican states which are home to 40% of all migrants to the U.S. were over-sampled at a rate of 1.7:1. Spouse/partners of eligible respondents were interviewed also, even if the spouse was born after 1950. Completed interviews were obtained in 9,862 households, for a total of 15,186 individual interviews. All interviews were face-to-face, with average duration of 82 minutes. A direct interview (on the Basic questionnaire) was sought, and Proxy interviews were obtained when poor health or temporary absence precluded a direct interview. Questionnaire topics included the following: * HEALTH MEASURES: self-reports of conditions, symptoms, functional status, hygienic behaviors (e.g., smoking & drinking history), use/source/costs of health care services, depression, pain, reading and cognitive performance; * BACKGROUND: Childhood health and living conditions, education, ability to read/write and count, migration history, marital history; * FAMILY: rosters of all children (including deceased children); for each, demographic attributes, summary indicators of childhood and current health, education, current work status, migration. Parent and sibling migration experiences; * TRANSFERS: financial and time help given to and received by respondent from children, indexed to specific child; time and financial help to parent; * ECONOMIC: sources and amounts of income, including wages, pensions, and government subsidies; type and value of assets. All amount variables are bracketed in case of non-response. * HOUSING ENVIRONMENT: type, location, building materials, other indicators of quality, and ownership of consumer durables; * ANTHROPOMETRIC: for a 20% sub-sample, measured weight, height; waist, hip, and calf circumference; knee height, and timed one-leg stands. Current plans are to conduct another two follow-up surveys in 2012 and 2014 and will field the 3rd and 4th waves of survey data collection in Mexico. For the 2012 wave, interviews will be sought for: every person who was part of the panel in 2003 and their new spouse / partner, if applicable, and a new sample of persons born between 1952 and 1962. For the 2014 wave, we will follow-up the whole sample from 2012. Interviews will be conducted person-to-person. Direct interviews will be sought with all informants, but proxy interviews are allowed for those unable to complete their own interview for health or cognitive reasons. A next-of-kin interview will be completed with a knowledgeable respondent for those who were part of the panel but have died since the last interview. A sub-sample will be selected to obtain objective markers such as blood sample and anthropometric measures. Data Availability: The 2001 baseline data, 2003 follow-up data, and documentation can be downloaded. * Dates of Study: 2001-2003 * Study Features: Longitudinal, International, Anthropometric Measures * Sample Size: 2001: 15,186 (Baseline) Link: * ICPSR: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/00142

Proper citation: Mexican Health and Aging Study (RRID:SCR_000818) Copy   

•   Source: SciCrunch Registry

http://www2.bsc.gwu.edu/bsc/oneproj.php?pkey=28

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. Collect, store, and distribute genetic samples from cases and controls of type 1 diabetes and diabetic nephropathy for investigator-driven research into the genetic basis of diabetic nephropathy. As the risk of kidney complications in type 1 diabetes appears to have a considerable genetic component, this study assembled a large data resource for researchers attempting to identify causative genetic variants. The types of data collected allowed traditional case-control testing, a rapid and often powerful approach, and family-based analysis, a robust approach that is not influenced by population substructure.

Proper citation: Genetics of Kidneys in Diabetes (RRID:SCR_000133) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=31576&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. PRACSIS (Prognosis and Risk in Acute Coronary Syndromes In Sweden) aims to study prognosis and its predictors in a consecutive series of patients with acute coronary syndrome (ACS). The study is comprised of patients between 18 and 80 years diagnosed at the coronary care unit at the Sahlgrenska University Hospital with unstable angina, non-ST-elevation MI or ST-elevation MI. Extensive information on medical history and blood samples for analyses of biochemical markers and genetic factors have been collected.

Proper citation: PRACSIS - Prognosis and Risk in Acute Coronary Syndromes In Sweden (RRID:SCR_000615) Copy   

•   Source: SciCrunch Registry

http://titan.biotec.uiuc.edu/bee/honeybee_project.htm

A database integrating data from the bee brain EST sequencing project with data from sequencing and gene research projects from other organisms, primarily the fruit fly Drosophila melanogaster. The goal of Bee-ESTdb is to provide updated information on the genes of the honey bee, currently using annotation primarily from flies to suggest cellular roles, biological functions, and evolutionary relationships. The site allows searches by sequence ID, EST annotations, Gene Ontology terms, Contig ID and using BLAST. Very nice resource for those interested in comparative genomics of brain. A normalized unidirectional cDNA library was made in the laboratory of Prof. Bento Soares, University of Iowa. The library was subsequently subtracted. Over 20,000 cDNA clones were partially sequenced from the normalized and subtracted libraries at the Keck Center, resulting in 15,311 vector-trimmed, high-quality, sequences with an average read length of 494 bp. and average base-quality of 41. These sequences were assembled into 8966 putatively unique sequences, which were tested for similarity to sequences in the public databases with a variety of BLAST searches. The Clemson University Genomics Institute is the distributor of these public domain cDNA clones. For information on how to purchase an individual clone or the entire collection, please contact www.genome.clemson.edu/orders/ or generobi (at) life.uiuc.edu.

Proper citation: Honey Bee Brain EST Project (RRID:SCR_002389) Copy   

•   Source: SciCrunch Registry

http://lgsun.grc.nia.nih.gov/cDNA/cDNA.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 23,2022. Project portal housing NIA Mouse EST Project, NIA Mouse cDNA Clone Sets, a NIA Mouse Gene Index, NIA Mouse cDNA Database, and NIA Mouse Microarrays. Characteristics of NIA 15K Mouse cDNA Clone Set * ~15,000 unique cDNA clones were rearrayed among 52,374 ESTs from pre- and periimplantation embryos, E12.5 female gonad/mesonephros, and newborn ovary. * Up to 50% are derived from novel genes. * ~1.5 kb average insert size. * Clones were sequenced from 5' and 3' termini to obtain longer reads and verify sequence. Sequence information is available at this Web Site. Clone names are from H3001A01 to H3159G07. * Handling of NIA 15k cDNA Clone Set(June3, 2000) Characteristics of NIA mouse 7.4K cDNA Clone Set * ~7407 cDNA clones with no redundancy within the set or with NIA Mouse 15K. * ~1.5 kb average insert size for short insert clones and ~2.5-3.0 kb average insert size for long-insert enriched clones.. * Clones were sequenced from 5' and 3' termini to obtain longer reads and verify sequence. Sequence information is available at this Web Site. Clone names are from H4001A01 to H4079G07. * Handling of NIA mouse 7.4k cDNA Clone Set (similar to handling of NIA mouse 15K, to be updated) Individual Clones are available from ATCC and MRC geneservice, UK. To obtain Clone, search the database using either the rearrayed clone name or GenBank accession number at the Key Word Search page. Follow the link to the sequence information page for the rearrayed clone to obtain source clone ATCC number. Clicking the ATCC number will bring up the ATCC ordering page for the source clone. There is essentially no overlap between the two clone sets (7.4K and 15K) said Minoru S.H. Ko, M.D., Ph.D., head of the Developmental Genomics and Aging Section in the NIA's Laboratory of Genetics. In addition, all cDNA clones in the NIA 7.4K set were purified by single colony isolation and sequence-verified, and more than half were prepared by a new procedure that yields long full-length cDNAs (average size 3-4 kb). The NIA Mouse 15k and 7.4k Clone Set Data and Published Microarray Data are available for download. NIA Mouse Microarrays *Microarray Data Download * 60-mer Oligo Array Platform ** (A) NIA 22k Oligo Microarray Gene List (21939 gene features) ( Carter et al 2003 ) ** (B) Agilent Mouse Development Oligo Microarray Gene List ** ( Subset of Microarray (A): 20,280 gene features ) * Data Analysis Tools

Proper citation: NIA Mouse cDNA Project Home Page (RRID:SCR_001472) Copy   

•   Source: SciCrunch Registry

http://www.diabetestrialnet.org/biobank/

Provides investigators with the opportunity to obtain on-demand biological samples from selected individuals that TrialNet has developed through the longitudinal monitoring of individuals at risk for the development of type 1 diabetes within the Natural History study. Exploratory research is encouraged under this initiative. Studies must use TrialNet screened subjects, and cannot interfere with ongoing clinical trials or studies. Investigators can select the clinical characteristics needed for their study as well as the sample type and collection frequency. Although many Living Biobank studies may be implemented through cost-sharing with the TrialNet network, special sample collections and visits outside of the normal visit schedules will incur additional costs which should be covered by the approved applicant. In addition, some studies may require effort from the TrialNet coordinating center, with costs covered by the approved ancillary study. Living biobank studies will be evaluated with careful consideration for their potential impact on the objectives and performance of the TrialNet Natural History study. To protect the interests of TrialNet, each living biobank study must be reviewed and approved by the Ancillary Studies Committee before its initiation. All approved living biobank studies will be reviewed yearly to evaluate their progress, and impact on TrialNet as a whole. TrialNet welcomes the submission of living biobank studies as an adjunct to ongoing protocols.

Proper citation: Living Biobank (RRID:SCR_001510) Copy   

•   Source: SciCrunch Registry

http://www.utsouthwestern.edu/labs/acute-liver/

Clinical research network for gathering prospective data and bio-samples on acute liver failure in adults since 1998. Clinical histories and laboratory and outcome data are available. Sample types include serum, plasma, urine, DNA, and liver tissue.

Proper citation: Acute Liver Failure Study Group (RRID:SCR_001463) Copy   

•   Source: SciCrunch Registry